Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis. - Wikidata - wikimedia - TriplyDB

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

http://www.wikidata.org/entity/Q34576320

about

Adverse effects of biologics: a network meta-analysis and Cochrane overview Population pharmacokinetic analysis of panitumumab in patients with advanced solid tumors Immunogenicity and Lupus-Like Autoantibody Production Can Be Linked to Each Other along With Type I Interferon Production in Patients with Rheumatoid Arthritis Treated With Infliximab: A Retrospective Study of a Single Center Cohort Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.Predicting pharmacokinetic profile of therapeutic antibodies after iv injection from only the data after sc injection in cynomolgus monkey.Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.Golimumab.Subcutaneous bioavailability of golimumab at 3 different injection sites in healthy subjects.Tumor necrosis factor-α signaling in macrophages.Safety and clinical efficacy of golimumab in the treatment of arthritides.Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor α.Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.Erythrodermic Psoriasis Treated with Golimumab: A Case Report.Randomised clinical trial: a placebo-controlled study of intravenous golimumab induction therapy for ulcerative colitis.Golimumab monotherapy in Japanese patients with active rheumatoid arthritis despite prior treatment with disease-modifying antirheumatic drugs: results of the phase 2/3, multicentre, randomised, double-blind, placebo-controlled GO-MONO study through Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn's disease Current status and challenges of cytokine pharmacology.Novel TNF antagonists for the treatment of rheumatoid arthritis.Golimumab pharmacokinetics in ulcerative colitis: a literature review Golimumab: a tumor necrosis factor alpha inhibitor for the treatment of rheumatoid arthritis.Golimumab and malignancies: true or false association?The efficacy and safety of golimumab in the treatment of arthritis.Combination systemic therapies in psoriatic arthritis.Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.Therapeutic monoclonal antibody concentration monitoring: free or total?Golimumab - a new tool in the armoury against inflammatory arthritis.Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.A guide to rational dosing of monoclonal antibodies.Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine.Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.Adverse effects of golimumab in the treatment of rheumatologic diseases.Intravenous golimumab in rheumatoid arthritis.Adverse reactions to biologic agents and their medical management.Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.New Insights into the Mechanisms of Action of Anti-Tumor Necrosis Factor-α Monoclonal Antibodies in Inflammatory Bowel Disease.Drugs for Autoimmune Inflammatory Diseases: From Small Molecule Compounds to Anti-TNF Biologics.

P2860

Q24234197-2B4630F8-0042-4E20-8752-0A72F613E1F2 Q28257098-3114F3CE-E756-4864-948E-0E7D215F6C97 Q28554222-A5F123A8-CF73-4D64-9F86-5007956A836B Q30240183-062CAB46-181F-4037-B52B-F01F56FB4EC8 Q30902172-5B370104-7878-4861-874D-81F7640B8101 Q31091923-ACFE606B-1BF6-4D3C-A7B6-298037B8B0DF Q31148686-232CE97C-20FE-4A49-AB3D-03D771DFD565 Q33956485-0829CEC4-16E6-4A21-A36F-5F342F6928BE Q33973884-10FA3F96-BB9E-4760-8DE1-285E8E9C6838 Q34092224-B0317CE0-2EA7-4376-ACD1-FC0C4BD6FA60 Q34614211-EFE826D3-F10C-48E6-BAA5-7D6CE04957FA Q34734335-C752A7E8-9B17-4DE6-87EA-3C888ED1F731 Q35026454-E5B8FF42-02F1-4227-85D5-2A5EEEFF7CA1 Q35183631-40B5EBEC-0D96-4524-BD03-474E12EA281A Q35232352-7DB14A87-F437-4936-8619-CD7A1777E181 Q35639941-C1DE81FE-147A-4AAD-9D42-33C3C631C1E7 Q35931950-CA6BBD3C-28BF-46E6-A62F-349536644400 Q36584389-CE5DDB20-3A1C-4833-A15C-9D5AE58E0752 Q37130039-42BD2355-BF9E-4A1B-87C4-C250691774B3 Q37275504-13B7BAC6-3C7C-4D19-AC8D-DA5BFF8D7B64 Q37445966-63F069DC-34A4-41C3-8CA2-AF4B5E40B9BF Q37650386-9B303744-B84B-4881-BC2A-3CDC1CE9906B Q37671983-F82FCAE0-476C-43B1-AE4A-C52695B9275C Q37684575-12508F00-590E-4B3B-8CA9-A2D6DF735BFD Q37725721-F0023FB2-339E-4352-888F-F5B4D86CF10C Q37760938-7A67EB51-689D-4174-9D13-48BCF2735D8C Q37776265-E9F91D56-81EB-403B-A755-2BABABDD4F96 Q37786627-2394AE4B-8CCB-4CDF-9511-1CE2AB13C536 Q37810218-44D9914D-D222-4505-A31C-787C5E7424A7 Q37829741-19040AB0-F533-4DFE-A14D-BFDF81EC7B61 Q37895016-135D7B85-3EE0-4C44-ADDF-71D816F4C8D0 Q37976878-D71DB410-389A-477D-AE71-05E9CDAE2A5C Q38063585-30957984-88AA-4F08-86E7-13631DED9753 Q38072598-52A6DC67-7F2E-4CE7-9E1C-BD8704A6CF09 Q38132273-E1EFCD6A-D754-42C9-BEC9-9B347E2CBF6A Q38211958-05FD0BFF-89E0-4371-9D79-DB6ED667D0DD Q38238948-07A3BFC0-F4C7-45FF-B02D-6C305D8B826A Q38540353-9F5A17AC-E35B-48D7-A8AE-B23DF993A132 Q38582765-BF2F4FCB-DD84-4393-B476-323C43D0D267 Q38645738-54452538-94B6-4AE9-B2B6-3B74B51A2D5B

P2860

Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.

http://www.wikidata.org/entity/Q34576320

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@ast

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@en

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@nl

type

label

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@ast

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@en

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@nl

prefLabel

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@ast

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@en

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@nl

P1433

Q34576320-6EF90B82-1CA5-4476-AD2B-9BADF6356D3A

P1476

Q34576320-2A212D4D-4F60-4642-A3F4-3A92E1931CFF

P2093

Q34576320-06481166-B81F-468A-8E52-A999059D3959

Q34576320-21014BC0-4648-49AB-8987-6C4E2FEE4421

Q34576320-524714D3-8DBF-407F-9109-33142E44DB33

Q34576320-72296CCF-FA7A-4A29-BDA2-B170713AF88E

Q34576320-7DBB57B3-E11A-4BA8-917F-951171BCAB19

Q34576320-91D99312-35C2-466B-A761-85100E956DD7

Q34576320-A4DFABC7-EE78-4FA3-A46C-A963D4F32F10

Q34576320-A5CEC47D-114C-4D9F-B50F-CDD087685EA9

Q34576320-AD4F9FC2-D445-44CC-B3AF-D6D0ADD901DD

Q34576320-AD69D2B7-2E18-497A-A847-B4023B6CF0DD

P2860

Q34576320-27B7AFCC-69F2-48F8-A046-1DD1F2CB6013

Q34576320-32B4BA81-A6FD-489A-AAF2-F07481BF82C4

Q34576320-41263C36-BAFB-41D9-8FFB-F622F508C503

Q34576320-46ED0630-B8A5-46DD-A9A4-5744F83E00BF

Q34576320-53EF4D14-2284-45CF-81C6-C343CF35DE30

Q34576320-99B45165-E372-452C-81B7-14E4F01A1ACE

Q34576320-D0E1EC6B-C0D4-4809-BF5A-A1C1216747DF

Q34576320-E2357EB1-29AD-4B0B-94B4-5D08E8AF0316

Q34576320-F69DE231-BE81-4DEC-8396-A65172311343

P304

Q34576320-758CDE01-6A16-4D69-9129-67F64DADCC1B

P31

Q34576320-7B1F6A8E-3B66-4D1B-9715-BFC239BE4CEF

P356

Q34576320-09329BA3-9A50-4FFC-991D-2F8507C2E474

P433

Q34576320-70C3952A-AE0C-4846-9817-33EF6A1D0AD5

P478

Q34576320-E6F2B708-8BE0-4F59-9AAB-110117126CEF

P577

Q34576320-4FA39951-907E-4EFD-9C52-F475B8444A79

P698

Q34576320-9DF66D94-CFF6-42F3-8C33-2A0DDE90A505

P921

Q34576320-00F6947B-9770-48FF-942B-FF7C9D2D9BA5

Q34576320-C55E22A7-0A12-470E-B196-91FC52AC95AC

Q34576320-FC51B23F-F6B0-41D4-8F84-82C46A0A6CAA

P356

0091270006298188

P1433

The Journal of Clinical Pharmacology

P1476

Pharmacokinetics and safety of ...... cts with rheumatoid arthritis.

@en

P2093

Charles Pendley

http://www.w3.org/2001/XMLSchema#string

Daniel Baker

http://www.w3.org/2001/XMLSchema#string

Daniel E Everitt

http://www.w3.org/2001/XMLSchema#string

Esther Bouman-Thio

http://www.w3.org/2001/XMLSchema#string

Gopi Shankar

http://www.w3.org/2001/XMLSchema#string

Haishan Jang

http://www.w3.org/2001/XMLSchema#string

Honghui Zhou

http://www.w3.org/2001/XMLSchema#string

Hugh M Davis

http://www.w3.org/2001/XMLSchema#string

Joseph C Marini

http://www.w3.org/2001/XMLSchema#string

Mahboob U Rahman

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of intravenous immunoglobulin: a systematic review.

Antibody pharmacokinetics and pharmacodynamics.

TNF alpha--a pivotal role in rheumatoid arthritis?

TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis.

Pharmacokinetics of piperaquine after repeated oral administration of the antimalarial combination CV8 in 12 healthy male subjects.

Pharmacologic target-mediated drug disposition.

The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.

Population pharmacokinetic modeling and model validation of a spicamycin derivative, KRN5500, in phase 1 study.

Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).

P304

383-396

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0091270006298188

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17322150

http://www.w3.org/2001/XMLSchema#string

P921